Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages 875-883

  Tan, Benjamin R ^a   Thomas, Fabienne ^a   Myerson, Robert J ^a   Zehnbauer, Barbara ^a   Trinkaus, Kathryn ^a   Malyapa, Robert S ^a   Mutch, Matthew G ^a   Abbey, Elliot E ^a   Alyasiry, Amer ^a   Fleshman, James W ^a   McLeod, Howard L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN; THYMIDYLATE SYNTHASE;

ABSCESS; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANEURYSM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CROHN DISEASE; DEHYDRATION; DIARRHEA; DNA POLYMORPHISM; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPNEA; ENTERITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HERNIA; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; ILEITIS; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PELVIS ABSCESS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM CARCINOMA; SMALL INTESTINE OBSTRUCTION; SYNCOPE; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 79952356214     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.3212     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
3. Roh MS, Colangelo LH, O'Connell MJ, et al: Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124-5130, 2009
4. Bosset JF, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114-1123, 2006 (Pubitemid 44394918)
5. Braendengen M, Tveit KM, Berglund A, et al: Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687-3694, 2008
6. Gérard JP, Conroy T, Bonnetain F, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 24:4620-4625, 2006 (Pubitemid 46630960)
7. Crane CH, Skibber JM, Birnbaum EH, et al: The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 57:84-89, 2003 (Pubitemid 36959742)
8. Read TE, McNevin MS, Gross EK, et al: Neoadjuvant therapy for adenocarcinoma of the rectum: Tumor response and acute toxicity. Dis Colon Rectum 44:513-522, 2001 (Pubitemid 32336425)
9. García-Aguilar J, Hernandez de Anda E, Sirivongs P, et al: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 46:298-304, 2003 (Pubitemid 36331646)
10. Onaitis MW, Noone RB, Hartwig M, et al: Neoadjuvant chemoradiation for rectal cancer: Analysis of clinical outcomes from a 13-year institutional experience. Ann Surg 233:778-785, 2001 (Pubitemid 32494558)
11. Spitz FR, Giacco GG, Hess K, et al: p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 3:1685-1690, 1997 (Pubitemid 27444705)
12. Tjandra JJ, Reading DM, McLachlan SA, et al: Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: Preliminary results. Dis Colon Rectum 44:1113-1122, 2001 (Pubitemid 32758266)
13. Mohiuddin M, Mohiuddin MM, Marks J, et al: Future directions in neoadjuvant therapy of rectal cancer: Maximizing pathological complete response rates. Cancer Treat Rev 35:547-552, 2009
14. Crane CH, Skibber JM, Feig BW, et al: Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97:517-524, 2003 (Pubitemid 36133820)
15. Rödel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688-8696, 2005 (Pubitemid 46211512)
16. Theodoropoulos G, Wise WE, Padmanabhan A, et al: T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45:895-903, 2002 (Pubitemid 34761469)
17. Valentini V, Coco C, Picciocchi A, et al: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664-674, 2002 (Pubitemid 34626505)
18. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994 (Pubitemid 24379651)
19. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412, 1995
20. Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229, 1997 (Pubitemid 27419335)
21. Lenz HJ, Danenberg KD, Leichman CG, et al: p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 4:1227-1234, 1998 (Pubitemid 28213334)
22. Lenz HJ, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182, 1996 (Pubitemid 26020011)
23. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000 (Pubitemid 30226214)
24. Horie N, Aiba H, Oguro K, et al: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191-197, 1995
25. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65-70, 2001 (Pubitemid 33757985)
26. Kawakami K, Omura K, Kanehira E, et al: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249-3252, 1999 (Pubitemid 30042617)
27. Villafranca E, Okruzhnov Y, Dominguez MA, et al: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779-1786, 2001 (Pubitemid 32230880)
28. Spindler KL, Nielsen JN, Lindebjerg J, et al: Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 50:1363-1369, 2007 (Pubitemid 47472390)
29. Ott K, Vogelsang H, Marton N, et al: The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 119:2885-2894, 2006 (Pubitemid 44846241)
30. Marsh S, Collie-Duguid ES, Li T, et al: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310-312, 1999 (Pubitemid 29300314)
31. Myerson RJ, Garofalo MC, El Naqa I, et al: Elective clinical target volumes for conformal therapy in anorectal cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas. Int J Radiat Oncol Biol Phys 74:824-830, 2009
32. Westra WH, Hruban RH, Phelps TH, et al: Surgical Pathology Dissection (ed 2). New York, NY, Springer Verlag, 2003
33. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
34. Bosset JF, Calais G, Mineur L, et al: Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results-EORTC 22921. J Clin Oncol 23:5620-5627, 2005
35. Aschele C, Pinto C, Cordio S, et al: Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 27:18s, 2009 (suppl; abstr 4008)
36. Mehta VK, Cho C, Ford JM, et al: Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132-137, 2003 (Pubitemid 36020352)
37. Klautke G, Feyerherd P, Ludwig K, et al: Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 92:1215-1220, 2005 (Pubitemid 40604394)
38. Navarro M, Dotor E, Rivera F, et al: A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66:201-205, 2006 (Pubitemid 44175647)
39. Mohiuddin M, Winter K, Mitchell E, et al: Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24:650-655, 2006 (Pubitemid 46630429)
40. Glynne-Jones R, Falk S, Maughan TS, et al: A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group Study. Br J Cancer 96:551-558, 2007
41. Iles S, Gollins S, Susnerwala S, et al: Irinotecan+5-fluorouracil with concomitant preoperative radiotherapy in locally advanced nonresectable rectal cancer: A phase I/II study. Br J Cancer 98:1210-1216, 2008 (Pubitemid 351481677)
42. Carlomagno C, Pepe S, D'Armiento FP, et al: Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Oncology 78:369-375, 2010
43. Negri FV, Campanini N, Camisa R, et al: Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 98:143-147, 2008
44. Capirci C, Valentini V, Cionini L, et al: Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: Long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72:99-107, 2008
45. de Campos-Lobato LF, Stocchi L, da Luz Moreira A, et al: Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers. Ann Surg Oncol 17:1758-1766, 2010
46. Mohiuddin M, Hayne M, Regine WF, et al: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 48:1075-1080, 2000
47. Gérard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644, 2010